More Life Company Signed Pharmacy Partnership

The firm entered a non-binding letter of intent to develop Quicksome-enabled prescription products with a U.S. partner.

Updated on Oct. 6, 2026 in Healthcare

Isometric editorial illustration of a glass beaker and dropper on a flat surface, representing pharmaceutical technology infrastructure. — The More Life Company Corp. signed a non-binding agreement with a U.S. compounding pharmacy to develop prescription products using its proprietary Quicksome delivery technology. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies use compounding pharmacies to accelerate the commercialization of new drug delivery technologies?

The More Life Company Corp. has signed a non-binding letter of intent with an unnamed U.S.-based 503A compounding pharmacy. The partnership aims to commercialize pharmaceutical products utilizing the company’s proprietary Quicksome technology.

Why it matters

This agreement provides a specialized infrastructure for the development and distribution of Quicksome-enabled prescription goods in the U.S. market. It follows the firm's recent completion of a human pharmacokinetic study regarding USP-grade testosterone.

The partnership involves a 503A-classified compounding pharmacy, a regulatory designation essential for the intended U.S. production scope. The deal follows recent human pharmacokinetic study results focusing on USP-grade testosterone applications.

The players

The More Life Company Corp.

A company that trades under the symbols MLCO on the CSE and TMLCF on the OTC market.

The details

The collaboration integrates proprietary Quicksome formulations with the partner's existing pharmacy and fulfillment infrastructure. Future development efforts will target specific applications, including hormone replacement, peptide treatments, and CoQ10 products.

October 6, 2026: The More Life Company announced the signed letter of intent.

Market Landscape

This strategic alliance allows the firm to leverage the regulatory framework established by Section 503A of the Federal Food, Drug, and Cosmetic Act to enter the U.S. market. By securing specialized compounding capacity, the company differentiates its proprietary delivery technology from broader pharmaceutical competitors.

Patients may eventually see new options for Quicksome-enabled hormone replacement and peptide therapies as the project moves toward implementation. The ultimate impact on retail pricing and product accessibility will depend on the finalization of the commercial relationship.

The takeaway

This partnership represents a critical step in moving proprietary drug-delivery technology from the study phase to practical commercial application. Developing a U.S.-based fulfillment network is essential for companies looking to scale specialized pharmaceutical products.